
First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis
Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today...